Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer

This publication has 16 references indexed in Scilit:

• Simulations Using a Drug–Disease Modeling Framework and Phase II Data Predict Phase III Survival Outcome in First-Line Non–Small-Cell Lung Cancer
  Clinical Pharmacology & Therapeutics, 2012
• International, Randomized, Placebo-Controlled, Double-Blind Phase III Study of Motesanib Plus Carboplatin/Paclitaxel in Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer: MONET1
  Journal of Clinical Oncology, 2012
• A Time to Keep and a Time to Cast Away Categories of Tumor Response
  Journal of Clinical Oncology, 2011
• Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer
  Cancer Chemotherapy and Pharmacology, 2010
• Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics
  Journal of Clinical Oncology, 2009
• On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies
  Clinical Pharmacology & Therapeutics, 2009
• Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development
  Clinical Pharmacology & Therapeutics, 2009
• New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
  European Journal Of Cancer, 2009
• Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 2007
• Model-based predictions of expected anti-tumor response and survival in phase III studies based on phase II data of an investigational agent
  Journal of Clinical Oncology, 2006